BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19690617)

  • 1. Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.
    Selbo PK; Rosenblum MG; Cheung LH; Zhang W; Berg K
    PLoS One; 2009 Aug; 4(8):e6691. PubMed ID: 19690617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.
    Weyergang A; Cheung LH; Rosenblum MG; Mohamedali KA; Peng Q; Waltenberger J; Berg K
    J Control Release; 2014 Apr; 180():1-9. PubMed ID: 24531010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome.
    Bull-Hansen B; Cao Y; Berg K; Skarpen E; Rosenblum MG; Weyergang A
    J Control Release; 2014 May; 182():58-66. PubMed ID: 24637464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
    Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
    Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor.
    Liu Y; Cheung LH; Marks JW; Rosenblum MG
    Int J Cancer; 2004 Feb; 108(4):549-57. PubMed ID: 14696119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.
    Bull-Hansen B; Berstad MB; Berg K; Cao Y; Skarpen E; Fremstedal AS; Rosenblum MG; Peng Q; Weyergang A
    Oncotarget; 2015 May; 6(14):12436-51. PubMed ID: 26002552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.
    Eng MS; Kaur J; Prasmickaite L; Engesæter BØ; Weyergang A; Skarpen E; Berg K; Rosenblum MG; Mælandsmo GM; Høgset A; Ferrone S; Selbo PK
    Photochem Photobiol Sci; 2018 May; 17(5):539-551. PubMed ID: 29565434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents.
    Liu Y; Cheung LH; Hittelman WN; Rosenblum MG
    Mol Cancer Ther; 2003 Dec; 2(12):1341-50. PubMed ID: 14707275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.
    Liu Y; Zhang W; Cheung LH; Niu T; Wu Q; Li C; Van Pelt CS; Rosenblum MG
    Neoplasia; 2006 May; 8(5):384-93. PubMed ID: 16790087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin.
    Rosenblum MG; Cheung LH; Liu Y; Marks JW
    Cancer Res; 2003 Jul; 63(14):3995-4002. PubMed ID: 12873997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
    Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Light-enhanced VEGF
    Weyergang A; Fremstedal AS; Skarpen E; Peng Q; Mohamedali KA; Eng MS; Cheung LH; Rosenblum MG; Waltenberger J; Berg K
    J Control Release; 2018 Oct; 288():161-172. PubMed ID: 30217739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity.
    Liu Y; Zhang W; Niu T; Cheung LH; Munshi A; Meyn RE; Rosenblum MG
    Neoplasia; 2006 Feb; 8(2):125-35. PubMed ID: 16611405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
    Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
    Martínez-Torrecuadrada JL; Cheung LH; López-Serra P; Barderas R; Cañamero M; Ferreiro S; Rosenblum MG; Casal JI
    Mol Cancer Ther; 2008 Apr; 7(4):862-73. PubMed ID: 18413799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Light-enhanced VEGF
    Longva AS; Berg K; Weyergang A
    Front Immunol; 2023; 14():1278000. PubMed ID: 38173721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.
    Parameswaran R; Yu M; Lyu MA; Lim M; Rosenblum MG; Groffen J; Heisterkamp N
    Leukemia; 2012 Aug; 26(8):1786-96. PubMed ID: 22373785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
    Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
    Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity.
    Stratford EW; Bostad M; Castro R; Skarpen E; Berg K; Høgset A; Myklebost O; Selbo PK
    Biochim Biophys Acta; 2013 Aug; 1830(8):4235-43. PubMed ID: 23643966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
    Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
    Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.